The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study (Nafamostat)

August 17, 2023 updated by: Wonju Severance Christian Hospital

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

Comparison nafamostat and low molecular weight heparin among dialysis patients

Study Overview


Enrolling by invitation

Intervention / Treatment

Study Type


Enrollment (Estimated)



  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kangwondo
      • Wonju, Kangwondo, Korea, Republic of, 26426
        • Yonsei Unviersity Wonju College of Medicin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers



Inclusion Criteria:

  • platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion Criteria:

  • cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: nafamostat
Patients received dialysis through nafamostat
Comparison effect of nafamostat and cnoxan
Other Names:
  • cnoxan
No Intervention: Cnoxane
Patients received dialysis through cnoxan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with severe bleeding
Time Frame: 6 month
Brain hemorrhage (on brain CT), gastrointestinal bleeding (on EGD)
6 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with dialysis circuit clot
Time Frame: 6 month
Dialysis circuit clotting due to not enough anticoagulation
6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

December 31, 2023

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

April 18, 2023

First Submitted That Met QC Criteria

May 22, 2023

First Posted (Actual)

May 25, 2023

Study Record Updates

Last Update Posted (Actual)

August 21, 2023

Last Update Submitted That Met QC Criteria

August 17, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?


Drug and device information, study documents

Studies a U.S. FDA-regulated drug product


Studies a U.S. FDA-regulated device product


This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact As soon as a change is implemented on, this will be updated automatically on our website as well.

Clinical Trials on Bleeding

Clinical Trials on Nafamostat Mesylate